Windtree Therapeutics, Inc.

Industry

  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
      • Pulmonary
  • Biotechnology
    • Large Molecule

Other Names/Subsidiaries

  • CVie Therapeutics
  • Discovery Labs
See more in Biomedtracker

Latest on Windtree Therapeutics, Inc.

Scrip

Finance Watch: Merrimack And LianBio Are Latest To Liquidate As Options Run Out

 
• By Mandy Jackson

The pace of new financings seems to be picking up in 2024 after a decline in the fourth quarter of 2023 relative to the last quarter of 2022, but some drug developers still are struggling to raise new

Scrip

Deal Watch: Ikena Cuts Staff After BMS Exits IO Partnership

 
• By Joseph Haas and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Ikena Cuts Back As BMS Unravels Partner

Scrip

Windtree’s Phase II Success In Cardiogenic Shock Could Lead To Heart Failure Opportunity

 
• By Joseph Haas

Windtree Therapeutics, Inc. hopes eventually to bring its first-in-class SERCA 2a activator istaroxime to market for treatment of acute heart failure, but along the way to getting potentially approva

Scrip

Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown

 
• By Mandy Jackson

The ongoing US government shutdown means that the Securities and Exchange Commission (SEC) can't process new filings for proposed stock offerings, which means that the usual rush of biopharmaceutical